TAIPEI, Taiwan, May 08, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology, and oncology, has once again been ranked in the top 5% in the “Corporate Governance Evaluation System” launched by Taiwan Stock Exchange Corporation (TWSE) and Taipei Exchange (TPEx) and conducted by the Securities and Futures Institute.
Evaluation indicators include the following categories: protecting shareholder rights and interests, treating shareholders equitably, enhancing board composition and operation, increasing information transparency, and putting corporate social responsibility into practice. These benchmarks were used to assess 861 TWSE- and 675 TPEx-listed companies; the two groups are then separately ranked and categorized into seven brackets of top 5%, 6% to 20%, 21% to 35%, 36% to 50%, 51% to 65%, 66% to 80%, and 81% to 100%. Among all 1,536 companies, only 33 have been able to remain in the top 5% for four consecutive years; TLC stands proud among these exceptional companies and is the only biotech company to have achieved the prestigious status for four years.
TLC listed on the TPEx in December 2012 and was ranked Grade A in the 2013 Information Disclosure and Transparency Ranking System. In the following year, it won the highest ranking of Grade A++ in the 2014 Information Disclosure and Transparency Ranking System, as well as a ranking of Top 5% in the first-ever Corporate Governance Evaluation System. As Corporate Governance Evaluation has adopted most of the key indicators in the Information Disclosure and Transparency Ranking System, the two evaluations merged into one starting in 2015. Since then, TLC has consistently been ranked in the prestigious top 5%.
About TLC
TLC (4152.TWO) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of best-in-class novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, while establishing drug levels at target tissues without incurring large systemic exposures. TLC’s BioSeizer™ technology enables local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ targeted delivery technology enables prolonged pharmacokinetic profiles and enhanced distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.